ECM1 Knockout HAP1 Polyclonal Cells constitute a CRISPR/Cas9-edited polyclonal knockout cell population featuring targeted disruption of the ECM1 gene. This gene-edited pool is generated in the HAP1 cell background and is designed for loss-of-function studies of extracellular matrix protein 1. The polyclonal format provides a heterogeneous population of knockout cells, enabling robust functional analyses without clonal selection bias.
The host HAP1 cell line is a fibroblast-like, near-haploid human cell line derived from the chronic myeloid leukemia line KBM-7. Its near-haploid karyotype facilitates straightforward gene targeting and phenotypic characterization, as the presence of a single gene copy reduces complementation effects. HAP1 cells are widely used in genetic screens, CRISPR knockout studies, and pathway dissection due to their ease of manipulation and stable growth characteristics.
ECM1 encodes a secreted glycoprotein that plays pivotal roles in extracellular matrix organization, bone formation, angiogenesis, and skin homeostasis. Mechanistically, ECM1 functions as a modulator of TGF-beta and Wnt signaling pathways. It is transcriptionally activated by TGF-beta and IL-4, and it interacts with multiple matrix components, including perlecan, fibulin-1, laminin, and MMP9. Downstream, ECM1 regulates MMP9 activation, collagen fibrillogenesis, and the expression of epithelial-mesenchymal transition (EMT) markers such as E-cadherin and vimentin. In TGF-beta signaling, ECM1 associates with betaglycan and influences SMAD2/3 phosphorylation, while in the Wnt pathway it modulates LRP5/6 co-receptor function and beta-catenin stability. Through these interactions, ECM1 coordinates cell adhesion, migration, and differentiation processes.
In the HAP1 background, ECM1 knockout provides a simplified genetic system to dissect its role in matrix remodeling and signal transduction. The near-haploid nature of HAP1 cells ensures that knockout phenotypes are directly attributable to ECM1 loss, avoiding confounding effects from wild-type alleles. This polyclonal population is particularly suited for studying acute versus chronic ECM1 deficiency and for screening chemical or genetic modifiers of ECM1-dependent pathways in a high-throughput format.
This knockout model supports a broad range of research applications, including investigations into cancer metastasis, skin barrier function, bone development, and TGF-beta signaling. Typical experimental approaches include Western blotting for ECM1 and EMT markers, RT-qPCR for gene expression analysis, cell migration and invasion assays, immunofluorescence to assess ECM1 localization, and phospho-signaling analysis of the TGF-beta pathway. For additional information and technical support, please contact Ascent Research.
